To gain insights into an N-terminal pro–B-type natriuretic peptide (NT-proBNP)–guided approach for cardioprotection in patients with breast cancer or lymphoma treated with anthracyclines and quantify the feasibility, tolerability, and exploratory efficacy of an NT-proBNP–guided strategy compared with usual care. Here, NPPB is linked to breast carcinoma.